Citigroup
RLMD icon

Citigroup’s Relmada Therapeutics RLMD Stock Holding History

Citigroup’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$107K Sell
15,414
-7,120
-32% -$33.7K ﹤0.01% 4255
2025
Q4 		$109K Buy
22,534
+22,532
+1,126,600% +$75.5K ﹤0.01% 4284
2025
Q3 		$4 Hold
2
– – ﹤0.01% 5994
2025
Q2 		$1 Hold
2
– – ﹤0.01% 5616
2025
Q1 		$1 Sell
2
-62,947
-100% -$20.9K ﹤0.01% 5528
2024
Q4 		$32.7K Sell
62,949
-2
-0% -$5 ﹤0.01% 5189
2024
Q3 		$204K Hold
62,951
– – ﹤0.01% 4332
2024
Q2 		$189K Sell
62,951
-60,862
-49% -$220K ﹤0.01% 3903
2024
Q1 		$576K Buy
123,813
+50,690
+69% +$244K ﹤0.01% 3467
2023
Q4 		$303K Sell
73,123
-26,400
-27% -$78.2K ﹤0.01% 3721
2023
Q3 		$299K Sell
99,523
-19,795
-17% -$58.8K ﹤0.01% 3417
2023
Q2 		$294K Buy
+119,318
New +$330K ﹤0.01% 3690
2023
Q1 		– Sell
-185
Closed -$646 – 5805
2022
Q4 		$646 Sell
185
-3,997
-96% -$35.1K ﹤0.01% 5469
2022
Q3 		$155K Sell
4,182
-58,519
-93% -$1.62M ﹤0.01% 3883
2022
Q2 		$1.19M Buy
62,701
+27,796
+80% +$606K ﹤0.01% 2515
2022
Q1 		$942K Buy
34,905
+29,891
+596% +$618K ﹤0.01% 3029
2021
Q4 		$113K Sell
5,014
-2,887
-37% -$64.2K ﹤0.01% 4669
2021
Q3 		$207K Buy
7,901
+4,166
+112% +$112K ﹤0.01% 4098
2021
Q2 		$120K Buy
3,735
+1,975
+112% +$68.6K ﹤0.01% 4449
2021
Q1 		$62K Sell
1,760
-2,748
-61% -$96.1K ﹤0.01% 4599
2020
Q4 		$144K Buy
4,508
+1,909
+73% +$65.6K ﹤0.01% 5243
2020
Q3 		$98K Sell
2,599
-2,423
-48% -$93.6K ﹤0.01% 5134
2020
Q2 		$224K Buy
5,022
+3,322
+195% +$140K ﹤0.01% 4929
2020
Q1 		$58K Buy
1,700
+764
+82% +$30.8K ﹤0.01% 5849
2019
Q4 		$37K Buy
+936
New +$28.4K ﹤0.01% 6562

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Citigroup's RLMD Position: Q1 2026 in Review

Citigroup reduced its Relmada Therapeutics (RLMD) stake by 32% in Q1 2026, selling an estimated $33.7K and leaving 15,414 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #4255.

Citigroup first reported a position in RLMD in Q4 2019 and has held it in 25 quarters since. The position peaked at $1.19M in Q2 2022. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Citigroup held 15,414 shares of Relmada Therapeutics worth $107K as of Q1 2026.
  • Citigroup sold 7,120 Relmada Therapeutics shares in Q1 2026, an estimated $33.7K.
  • Relmada Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4255 holding.
  • Citigroup first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 25 quarters since.
  • Citigroup's Relmada Therapeutics position peaked at $1.19M in Q2 2022.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.